Citi Reaffirms Buy Rating on CSPC Pharma, Sets Price Target at HK$11.50
Deep News
Jul 29
Citi recently released a research report stating that CSPC PHARMA (01093) has issued a profit alert. The company expects its net profit for the first half of the year to range between 5.9 billion and 6.2 billion yuan, compared to 2.55 billion yuan in the same period last year.
This implies a year-on-year growth of 131% to 143%, significantly surpassing the market's forecast of 2.5 billion yuan. The bank believes that CSPC PHARMA's performance far exceeded expectations.
As a result, Citi has listed the company as one of its top picks in the pharmaceutical sector and maintained its "Buy" rating along with a price target of HK$11.5.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.